A medication approved to cure a serious form of asthma radically enhanced the well-being of people having rare chronic immune disorders known as HES (hypereosinophilic syndromes) in whom other therapies were intolerable or ineffective. This outcome comes from a small medical trial conducted by researchers at the NIAID (National Institute of Allergy and Infectious Diseases)—which is a part of the NIH (National Institutes of Health)—and carried through a collaboration with the international biopharmaceutical company AstraZeneca. The study was published in the New England Journal of Medicine.
Anthony S. Fauci—NIAID’s Director—said, “People having a rare disease mostly have less—if any—efficient treatment options. This potential treatment advance for individuals having hypereosinophilic syndromes is just one instance of how NIH research reacts to the rare medical needs of people having rare diseases.” Reportedly, HES is caused by elevated-than-normal numbers of WBCs (white blood cells) known as eosinophils in the tissues, blood, or both. While most of the people have 0–500 eosinophils per microliter of blood, people having HES naturally have over 1,500 eosinophils per microliter. The symptoms of HES differ extensively from one patient to other and can impact the lungs, heart, skin, central nervous system, gastrointestinal tract, and other organ systems.
Recently, the NIAID was in news reporting that opioid outbreak is surging rates of certain infectious diseases. The U.S. encounters a converging civic health crisis as the country’s opioid epidemic boosts increasing rates of some infectious diseases, counting hepatitis, HIV/AIDS, skin and soft tissue infections, and heart infections. As per a new explanation in the Journal of Infectious Diseases, infectious disease and professionals must work together to explore the escalating public health threat. The article was co-authored by officers from the NIAID and the IHV (Institute of Human Virology) of the UMB (University of Maryland School of Medicine, Baltimore).